Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic colorectal cancer, an aggressive subtype with a poor prognosis, was compared with standard care (chemotherapy with or without bevacizumab) in an open-label, phase 3 trial, which showed significance regarding one of the two primary end points, objective response according to blinded independent central review (odds ratio for EC+mFOLFOX6 vs. standard care, 2.44; one-sided P<0.001). This result led to accelerated Food and Drug Administration approval of this investigational combination therapy for BRAF V600E–mutated metastatic colorectal cancer, including as first-line therapy. Data on progression-free survival (the second primary end point) and an updated interim analysis of overall survival are now available. Methods We randomly assigned patients with untreated BRAF V600E–mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care. The two primary end points were objective response (reported previously) and progression-free survival according to blinded independent central review in the EC+mFOLFOX6 group and the standard-care group. The key secondary end point was overall survival. Results Significantly longer progression-free survival was seen with EC+mFOLFOX6 than with standard care (median, 12.8 vs. 7.1 months; hazard ratio for progression or death, 0.53; 95% confidence interval [CI], 0.41 to 0.68; P<0.001). In an interim analysis, overall survival was significantly longer with EC+mFOLFOX6 than with standard care (median, 30.3 vs. 15.1 months; hazard ratio for death, 0.49; 95% CI, 0.38 to 0.63; P<0.001). The incidence of serious adverse events during treatment was 46.1% with EC+mFOLFOX6 and 38.9% with standard care. Safety profiles were consistent with those known for each agent. Conclusions This trial showed significantly longer progression-free survival and overall survival with first-line treatment with EC+mFOLFOX6 than with standard care among patients with BRAF V600E–mutated metastatic colorectal cancer. (Funded by Pfizer and others; BREAKWATER ClinicalTrials.gov number, NCT04607421 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recently, the BREAKWATER trial demonstrated significant improvements in progression-free survival and overall survival after combining encorafenib and cetuximab with first-line chemotherapy, establishing a new treatment paradigm for patients with BRAF-mutant mCRC [57].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Self-citationCorcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Tran, B., Kopetz, S., Tie, J., Gibbs, P., Jiang, Z., Lieu, C. H., Agarwal, A., Maru, D. M., Sieber, O., & Desai, J. (2011) · Cancer · doi:10.1002/cncr.26086 · Cited by 797
Self-citationPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
Self-citationTreatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
Self-citationCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Self-citationCorcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Self-citationA graphical approach to sequentially rejective multiple test procedures
Bretz, F., Maurer, W., Brannath, W., & Posch, M. (2009) · Statistics in Medicine · doi:10.1002/sim.3495 · Cited by 420
Cited by
Items 101–174 of 174
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127 · Cited by 1
Sah, N., Omy, T. R., Kairamkonda, S., Acharya, G., Palle, H., Luna, P., Mani, C., Gmeiner, W. H., Cheedella, N. K., Reedy, M. B., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.05.716582
“50,58,59 While these combinations can extend disease control, they are often limited by a narrow therapeutic window and cumulative toxicities.”
New prognostic and predictive scoring systems for colorectal cancer liver metastases
Salvà, F., Pérez-Fernández, S., Dopazo, C., Salcedo, M., Gonzalez, N. S., Rodríguez-Castells, M., Baraibar, I., Ros, J., de Torres, C. S., Vaghi, C., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.106923
Self-citationBurge, M., Tie, J., Krishnan, T., Roy, A., Chantrill, L., Tebbutt, N. C., Karapetis, C. S., & Price, T. J. (2026) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2026.04.001 · Cited by 1
Evolving therapeutics in colorectal cancer peritoneal metastases
Bader, J. M., Aguirre, N., Schultz, K. S., Ofori, K. A., Godfrey, E., Gupta, P., Tseng, R., Cecchini, M., Sundar, R., & Turaga, K. K. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10335-0 · Cited by 1
Grancher, A., Landi, M., Ballhausen, A., Tocino, R. V., Alig, A. H. S., Taravella, A., Malicot, K. L., Soularue, É., Gallois, C., Guarssifi, M., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.04.009
Circulating tumour DNA in colorectal cancer: current and emerging clinical applications
O’Rourke, H., & Tie, J. (2026) · Academia oncology. · doi:10.20935/acadonco8279 · Cited by 1
CDA-AMC (2026) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2026.1429
Yang, Y.-H., Starling, N., & Cartwright, E. (2026) · The Oncologist · doi:10.1093/oncolo/oyag161 · Cited by 1
赵欣, Guo, S., Shen, R., Zhang, W., & Zhang, Y. (2026) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-163955
Luo, S., Cai, Y., Wang, X., Lan, H., Yang, L., Lin, S., Huang, X., Weng, X., & Xu, X. (2026) · The Pharmacogenomics Journal · doi:10.1038/s41397-026-00417-1
“…achieved a median progression-free survival (PFS) of 12.8 months (hazard ratio [HR]: 0.53; 95% con fi dence interval [CI]: 0.407 – 0.677; P < 0.0001) and extended the median OS to 30.3 months (HR: 0.49; 95% CI: 0.375 – 0.632; P < 0.0001), bringing a glimmer of hope for survival to patients [8].”
InfluentialDemirhan, Y. E., Gill, A., Yoakam, M., & Dalia, S. M. (2026) · Tumor Discovery · doi:10.36922/td026060012
Atallah, S. (2026) · Springer eBooks · doi:10.1007/978-3-032-21069-2_26
Emerging role of antibody–drug conjugates in gastrointestinal malignancies
Khan, U., & Shah, M. A. (2026) · Cancer · doi:10.1002/cncr.70419
Andrews, H., Agnihotram, R., Blumenthal, G. M., Bullock, J. M., Collins, G., Doherty, G. J., Farago, A. F., Ishii, Y., Kasichayanula, S., LeBlanc, M. L., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag222
Advances in multimodal therapy for peritoneal metastasis from colorectal cancer
Cao, Y.-Q., Wu, Q.-B., Wang, Z., & Meng, W. (2026) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v34.i5.404
Aguiari, G., Bianchi, N., & Franzese, O. (2026) · Cells · doi:10.3390/cells15121074
Kolorektales Karzinom – Update: Was ist neu in der S3-Leitlinie?
Pox, C. P. (2026) · Gastroenterologie up2date · doi:10.1055/a-2408-5559
作山洋貴, Okuyama, H., Tahara, Y., Tsukamoto, S., Kita, I., Nomura, K., Murakami, A., Okita, Y., Satake, H., Kato, T., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03101-3
Zhong, C., Huang, F., Li, D., Jiang, K., He, Y., Yuan, Y., & Weng, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9805547/v1
Modulating the Tumor Microenvironment: Small-Molecule Strategies in Combination Regimens
Daripa, S., & Hira, S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-9777-2_12
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01524-9
Abdelhafeez, A. A., Dkhil, M. A., Kasem, S. M., Elabed, S., THAGFAN, F. A., & Abdalla, M. A. (2026) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-026-02107-y
“After incubation, the remaining settled oocysts were gently mixed with 0.1% eosin stain for 15 min to determine viability [45].”
InfluentialLee‐Ying, R. M., Gill, S., Box, A. H., Latour, H., Strum, S. W., Gordon, V. L., Wong, R., Grendarova, P., Gimon, T. I., Ahmed, S., et al. (2026) · Current Oncology · doi:10.3390/curroncol33070437
“EC alone in arm A was stopped after 158 patients were enrolled and the remaining patients were randomized to arm B or C after a protocol amendment [41].”
InfluentialLiesegang, A. G., Powell, H., Jain, A., Flood, M., Mohan, H. M., Warrier, S., Clemons, N. J., Ramsay, R. G., Tie, J., Michael, M., et al. (2026) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000004379
Jelas, I., & Stintzing, S. (2026) · Trillium Krebsmedizin · doi:10.47184/tk.2026.04.4
New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer
Takahashi, M., Taniguchi, S. H., & Yoshida, Y. (2026) · Cancer Science · doi:10.1111/cas.70480
“We are now preparing to initiate a clinical phase I study to find optimal doses of retinoids in combination with BRAF inhibition-based therapy in the later-line setting [31] (Figure 2).”
InfluentialDoermann, A. S., Caspi, A., Evans, A. E., Feci, A., Entezari, A. A., Snook, A. E., & Waldman, S. A. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683096 · Cited by 1
“…the addition of BRAFi and EGFRi to first-line standard therapy, significantly improved survival outcomes compared to standard therapy, in BRAF V600E-mutated metastatic CRC. 111,112 Following the success of MAPK pathway blockade in BRAF-mutant CRC, KRAS inhibitors are now being clinically evaluated.”
Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer
Srouji, N. A., Ismaiel, A., Puia, A., Ismaiel, M., Abosheisha, M., Popa, S., & Puia, I. C. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04531-1
Feng, M., Wu, X., Jiang, L., Huang, J., Zhang, J., Chen, P., & Chang, C. (2026) · Cancers · doi:10.3390/cancers18162552 · Cited by 1
Usón, P. L. S., Reuther, J., Golafshar, M. A., Hawley, M. H., Lavy, E., Young, S. M. N., Bekaii‐Saab, T., Wu, C., Korn, W. M., Esplin, E. D., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101093
“Since these data were collected, BRAF inhibitors, immunotherapy, and KRAS inhibitors were incorporated into the treatment landscape of advanced CRC. 33–35 Approximately, only 10% of patients were negative for variants of established or potential clinical significance.”
Self-citationDirven, I., Ang, C., Bertels, C., Kortbeek, K., de Haar-Holleman, A., Vollebergh, M. A., Poulikakos, P. I., & Neyns, B. (2026) · Cancer · doi:10.1002/cncr.70569
Benidovskaya, E., Huyghe, N. D., Giolito, M. V., Coulie, P. G., & den Eynde, M. V. (2026) · Cancers · doi:10.3390/cancers18162651
“BRAF V600E mutations (~10% of mCRC) confer poor prognosis and support the use of targeted therapies such as encorafenib plus cetuximab, combined with chemotherapy [16–19].”
Barreto, S. G., Karapetis, C. S., Ullah, S., Burge, M., Caird, S., Campbell, A., Jalali, A., Jennens, R. R., Khattak, M. A., Lee, B., et al. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70266
“However, data from the BREAKWATER trial suggest that incorporating targeted therapy (encorafenib and cetuximab) with chemotherapy may improve outcomes in BRAF V600E-mutant disease, including EOCRC, with potential implications for management of this historically poor prognosis subgroup [22, 23].”
Matsubara, Y., & Kawazoe, A. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2717151
“Encorafenib plus cetuximab in combination with FOLFOX demonstrated survival benefits among patients with BRAF V600E-mutated mCRC [5].”
Kwiatkowska, L., & Szczuko, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177559
“The analysis also showed a significant improvement in median PFS (12.8 vs. 7.1 months; HR 0.53) and OS benefit (overall survival), which led to the FDA registering the regimen in the first-line treatment [54].”
InfluentialYildiz, N. D., Arslan, Ç., Ökten, I. N., Kefeli, U., Yıldırım, M. E., Karadurmus, N., Baydas, T., Karabulut, B., Çiçin, İ., Bilir, C., et al. (2026) · Clinics and Practice · doi:10.3390/clinpract16090158
“Contemporary first-line treatment of BRAF V600E-mutant metastatic colorectal cancer has also evolved following the BREAKWATER trial evaluating encorafenib, cetuximab, and mFOLFOX6 [21].”
Xu, D., He, M., Liu, H., Zhong, R., Chen, M., Ye, F., Liu, Z., Shi, Y., & Huang, L. (2026) · Research Square · doi:10.21203/rs.3.rs-10679194/v1
BRAF V600E-Mutated Metastatic Colorectal Cancer: Practical Management in the Post-BREAKWATER Era
Sagawa, T., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01581-0
Wu, L. W., Park, J., Jang, S., & Moy, R. H. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00389
RAS-targeted therapies for pancreatic cancer
Chan, L. L., Kwong, T. T., Yau, J., & Chan, S. L. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100414
“59,60 However, the optimal combinatorial partner for RAS inhibitors in PDAC remains to be investigated.”
Thanabalachandran, L., Ali, D., Newman-Simmons, A., Norman, C., Jafari, D., Grahovac, T., Pollett, A. F., Huang, W., Chen, L., Kassam, S. N., et al. (2026) · Current Oncology · doi:10.3390/curroncol33090540
Organerhalt beim Rektumkarzinom
Fokas, E., Dapper, H., Diefenhardt, M., Damanakis, A. I., Schiffmann, L., Fuchs, H., Bruns, C., Rödel, C. M., & Dieplinger, G. (2026) · Die Onkologie · doi:10.1007/s00761-026-02015-z
What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas?
Sørbye, H., McNamara, M. G., Tesselaar, M. E. T., Cives, M., Knappskog, S., Perren, A., & Strosberg, J. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01833-z
“The BRAF-inhibitor encorafenib has been approved in combination with FOLFOX and cetuximab as first-line treatment for patients with any metastatic colorectal primary with BRAF V600E mutation [55].”
Tojjari, A., Pourbahrighesmat, S., Alkhazna, S., & Saeed, A. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105597
Aceituno, L., Valenzi, E., Segatto, O., Saborowski, A. L., & Vogel, A. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.102619
A Seamless Phase I/ II Design With Randomization for Biomarker‐Guided Oncology Trials
Zabor, E. C., Govande, S., Ma, W. W., & Hobbs, B. P. (2026) · Pharmaceutical Statistics · doi:10.1002/pst.70124
External Validation of the ARCAD Nomogram in a Real-World Cohort with Stage 4 Colorectal Cancer
Yu, J. B., Li, J., Schell, M. J., Ginestet, P. G., Zalcberg, J. R., Simes, R. J., Marschner, I., Kim, R. D., & Sjoquist, K. M. (2026) · Cancers · doi:10.3390/cancers18183031
“Furthermore, recent therapeutic advances utilizing targeted approaches for KRAS G12C and BRAF V600E mutations were not incorporated into this real-world dataset, limiting the evaluation of their specific prognostic impact [28–31].”
Gonçalves, M. P. C., Trocoli-Couto, P. H. F. S., Marchiodi, A. H., de Carvalho, L. T. B., Yamashita, Y. P. H., Lima, H. A., & Resende, V. (2026) · Cancers · doi:10.3390/cancers18193070
“As immunotherapy combinations and novel targeted agents (e.g., BRAF-and KRAS G12C-directed regimens) reshape treatment even in traditionally resistant subgroups [28–32], their interaction with surgical strategy will grow more complex, reinforcing the need for a unified, biology-driven approach.”
Ebright, R. Y., He, Y., Zhang, A. G., McCabe, I. C., Joisa, C. U., Thakar, T., Jen, J., Frederick, D. T., Acosta, A., Li, G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.24.754062
Shi, X., Zhang, P., Cui, X., Hou, Y., Zhang, D., Zhao, Y., Cao, L., Yong, S., Zhou, N., & Wang, J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158837
Yang, Y., Li, H., Xiao, S., Jiao, M., De, W. U., Ao, C., Zhang, Y., Yan, S., Sun, S., Yang, C., et al. (2026) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70118
“Recent studies evaluating various combinations of targeted and/or immunotherapies have shown that dual-and triple-targeted therapy strategies yield the best outcomes in terms of overall survival (OS) and progression-free survival [22].”
Kalil, J. A., Adam, R. A., Meti, N., & Metrakos, P. P. (2026) · Cancers · doi:10.3390/cancers18193169 · Cited by 1
“…standard, demonstrating median OS of 30.3 versus 15.1 months with standard care (HR 0.49, p < 0.001) and median PFS of 12.8 versus 7.1 months (HR 0.53, p < 0.001)—bringing survival in BRAF-mutant disease closer to that of BRAF wild-type patients [79,80]. https://doi.org/10.3390/cancers18193169”
InfluentialWan, K., Tang, K., Wang, L., Tian, Q., Zheng, M., Qian, C., & 刘丽梅 (2026) · MedComm · doi:10.1002/mco2.71028
“For poor-prognosis subgroups, such as BRAF V600E-mutant CRC, combination strategies targeting BRAF and EGFR have significantly improved outcomes, reflecting the need to overcome pathway reactivation [ 39 ].”
Fattakhova, A. S., Валентинович, Ч. С., & Shiryaev, N. P. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-15-46-53
Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma
Yamazaki, S., Hondo, N., Yasukawa, K., Kitazawa, M., Nakamura, S., Yamamoto, Y., Miyazaki, S., Tanaka, H., Kuroiwa, M., Ishizaka, N., et al. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00835-8
“More recently, addition of cytotoxic chemotherapy to this targeted combination further enhanced the therapeutic efficacy, establishing a new first-line treatment paradigm [36].”
Liberko, M. (2026) · Onkologie · doi:10.36290/xon.2026.040
Jin, X., Yang, S., Wang, Q., Chen, S., Wang, Y., & Yang, Y. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2747402
“7 as a key anti-apoptotic protein, B-cell lymphoma 2 (Bcl-2) contributes to tumour cell survival and has become an established target in anticancer drug development.”
Sagawa, T., Hirakawa, M., Nagashima, H., & Fujikawa, K. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01611-x
“For rapid, threatening progression, cytotoxic chemotherapy may be required; BREAKWATER supports encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E mCRC, although not specifically after dual ICI [47 ].”
Frühes und metastasiertes CRC - Neue Daten in der Adjuvanz und zu zielgerichteten Therapien
Arnheim, K. (2026) · Onkologische Welt · doi:10.1055/a-2920-9749
S3-Leitlinie Kolorektales Karzinom: Version 3.2 – März 2026 – AWMF-Registernummer: 021-007OL
Pox, C. P., Reichermeier, S., Aretz, S., Graeven, U., Hüneburg, R., Hüppe, D., Koch, C., Köhne, C.-H., Kolligs, F. T., Ludwig, L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2853-0320
Pascu, A., Ianole, V., & Danciu, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209346
“As an example, a phase III clinical trial has reported twofold longer OS in the mFOLFOX6 + anti-EGFR + anti-BRAF arm compared with the standard-of-care arm (NCT04607421 [15]).”
InfluentialMultimodal treatment of isolated leptomeningeal relapse in BRAF-mutated dMMR colon cancer
Weber, K., Völkl, A., Heinemann, V., & Boeck, S. H. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117795
XDH Inhibits the Progression of Colorectal Cancer via Regulating Ferritinophagy Signaling
Zhang, H., Yan, M., Li, M., Gu, J., Wang, X., Ding, J., & Luo, S. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.71145
“Although great breakthroughs have been made in the treatment of CRC, such as targeted therapy, immunotherapy, and nanomedicine, the overall survival rate of advanced CRC is less than 15% [3, 4].”
Kazmi, S. K., Rehman, M. A., Tariq, H., Kabir, A., Ahmed, J., & Yee, N. S.-S. S. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-026-01597-6
“This finding is inconsistent with level 1 evidence from the BEA - CON CRC and BREAKWATER trials, both of which demon - strated superior efficacy with combined pathway inhibition in randomized head-to-head comparisons [15, 16].”
Müller, M., Aparicio, T., Cohen, R., Gallois, C., Delattre, A., Paillaud, É., Mazard, T., Pelkowski, M., Phelip, J., Randrian, V., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.10.010
Early-onset colorectal cancer: from biology to clinical care and survivorship
Lefas, A. Y., Athauda, A., & Hogan, N. (2026) · Academia oncology. · doi:10.20935/acadonco8559
Colorectal Cancer Biomarkers: The Expanding Landscape
Rakoczy, K., Herbetko, A., Suwała, S., Czarny, J., Rudno‐Rudzińska, J., Milbrandt, O., & Kulbacka, J. (2026) · Cells · doi:10.3390/cells15211979
Burasakarn, P., Ponghussaban, K., Chalokool, V., Thienhiran, A., Hongjinda, S., & Fuengfoo, P. (2026) · Livers · doi:10.3390/livers6060112
The Modern Continuum of Care for Colorectal Liver Metastases: A Comprehensive Review
Burasakarn, P., Ponghussaban, K., Chalokool, V., Thienhiran, A., Hongjinda, S., & Fuengfoo, P. (2026) · The American Surgeon · doi:10.1177/00031348261504348
The genomic and epigenomic evolution of colorectal cancer
Sng, C. C. T., Starling, N., Graham, T. A., & Sottoriva, A. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01265-x
Krichen, J., Sghaier, A., Guizani, M., Saad, M. B., Faidi, B., Salah, K. B., Farah, F., & Ghzel, R. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1976305
Immunomodulatory and targeted therapies for metastatic colorectal cancer
Gao, K., Lv, Q., Lidan, Z., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1975205
Tímár, J., Rásó, E., Barbai, T., Baranyi, M., Kenessey, I., Pápai, Z., & Uhlyarik, A. (2026) · Pathology & Oncology Research · doi:10.3389/pore.2026.1612560
Metadata
- Authors
- Elez, E., Yoshino, T., Shen, L., Lonardi, S., Van Cutsem, E., Eng, C., Kim, T. W., Wasan, H. S., Desai, J., Ciardiello, F., Yaeger, R., Maughan, T. S., Morris, V. K., Wu, C., Usari, T., Laliberte, R., Dychter, S. S., Zhang, X., Tabernero, J., & Kopetz, S.
- Affiliations
- Vall d’Hebron Hospital Campus, Barcelona
- National Cancer Center Hospital East (JP)
- Peking University Cancer Hospital (CN)
- Istituto Oncologico Veneto (IT)
- University Hospitals Gasthuisberg Leuven, Leuven, Belgium
- Vanderbilt University (US)
- Asan Medical Center (KR)
- Hammersmith Hospital (GB)
- The University of Melbourne (AU)
- University of Campania "Luigi Vanvitelli" (IT)
- Memorial Sloan Kettering Cancer Center (US)
- University of Liverpool, Liverpool, United Kingdom
- The University of Texas MD Anderson Cancer Center (US)
- Mayo Clinic Hospital (US)
- Pfizer, Milan
- Pfizer (United States) (US)
- Universitat de Vic - Universitat Central de Catalunya (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-26
- Volume
- 392
- Issue
- 24
- Pages
- 2425-2437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC12197837
- OpenAlex
- W4410875702
- Cited by
- 166
- References
- 20
- Citations by year
- 2026: 125 · 2025: 41
- FWCI
- 67.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Pfizer, Inc.
- Clinical Center (Core Grant P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, mFOLFOX6, BRAF V600E mutation, metastatic colorectal cancer, first-line therapy, progression-free survival, overall survival, oxaliplatin, bevacizumab, targeted therapy, drug safety, serious adverse events, EGFR inhibition, BRAF inhibitor combination therapy
- MeSH terms
- Cetuximab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carbamates, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Organoplatinum Compounds, Sulfonamides, Colorectal Neoplasms, Treatment Outcome, Proto-Oncogene Proteins B-raf, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.